Oxidative DNA Damage by N4-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir.

Hatasu Kobayashi, Yurie Mori, Sharif Ahmed, Yuichiro Hirao, Shinya Kato, Shosuke Kawanishi, Mariko Murata, Shinji Oikawa

Journal: The Journal of infectious diseases 2023;227(9):1068-1072

PMID: 36461940

Abstract

Molnupiravir is an antiviral agent recently used for treating coronavirus disease 2019 (COVID-19). Here, we demonstrate that N4-hydroxycytidine (NHC), a molnupiravir metabolite, treated with cytidine deaminase (CDA) induced Cu(II)-mediated oxidative DNA damage in isolated DNA. A colorimetric assay revealed hydroxylamine generation from CDA-treated NHC. The site specificity of DNA damage also suggested involvement of hydroxylamine in the damage. Furthermore, Cu(I) and H2O2 play an important role in the DNA damage. We propose oxidative DNA damage via CDA-mediated metabolism as a possible mutagenic mechanism of NHC, highlighting the need for careful risk assessment of molnupiravir use in therapies for viral diseases, including COVID-19.

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Address: Department of Environmental and Molecular Medicine, Mie University Graduate School of Medicine, Tsu, Japan.; Department of Environmental and Molecular Medicine, Mie University Graduate School of Medicine, Tsu, Japan.; Faculty of Pharmacy, Gifu University of Medical Science, Kani, Japan.; Department of Environmental and Molecular Medicine, Mie University Graduate School of Medicine, Tsu, Japan.; Mie Prefectural College of Nursing, Tsu, Japan.; Radioisotope Experimental Facility, Advanced Science Research Promotion Center, Mie University, Tsu, Japan.; Faculty of Pharmaceutical Science, Suzuka University of Medical Science, Suzuka, Japan.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.